Cancer is a package of diseases marked by uncurbed growth and proliferation of anomalous cells. The illness is generally assumed to be the fruit of the impact of assorted outside factors and inner forces, such as tobacco smoking, radiation exposure, chemicals’ influences, infectious agents, inherited gene mutations, hormonal disorders, immune system conditions and mutations of other origins, among others.
Thus far, the Cancer Market has already seen noticeable progress in early-stage tumor detection and cure globally. The market for Cancer diagnostics is close to explosive growth, promising to reach approximately EUR 4 billion in value by end-2015. Further, technology discoveries will continue to afford many chances of demystifying the genetic components of the sickness, identifying specific tumor types, and observing biological reaction to cancer treatments. However, the bulk of presently available therapies do not fully protect against some unwelcomed side-effects.
The research reports in this Catalogue present global, regional and nation-level analyses of the Cancer Market development trends over different time spans. The research reports identify major bizopps emerging in the Cancer Market; examine versatile Cancer diagnostic test technologies along with their applications, besides looking into other Cancer Market issues. The research reports also profile the top players and would-be entrants, as well as offer test volume and sales projections.
Publications found:
1,866
Sort by:
2017 Cancer Diagnostic Instrumentation and Strategic Profiles of Leading Suppliers
US$ 3,465.00
... 119-page report reviews current instrumentation technologies, and compares features of major automated and semiautomated analyzers ... presents strategic assessments of current and emerging suppliers of tumor marker diagnostic products, including their sales, product portfolios, distribution tactics, ...
January 2017
119 pages
2017 World Cancer Diagnostics Market: North America, Europe, Asia-Pacific, LATAM, Africa, Middle East--Sales Forecasts and Strategies, Supplier Shares--Emerging Tumor Markers, Technologies and Opportunities
US$ 61,740.00
... specific opportunities and growth strategies for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs ... of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological ...
January 2017
1450 pages
Europe Cervical Cancer Test Market, Patients, By Screening Type (Pap Smear, HPV DNA) (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, Netherlands)
US$ 1,250.00
... Germany, France and United Kingdom are top three dominating countries in the Europe cervical cancer market in 2015. Europe Cervical Cancer Test Market, Patients, By Screening Type (Pap Smear, HPV DNA) (United Kingdom, France, Germany, Italy, Spain, Sweden, Switzerland, Norway, Netherlands) is 119 Page market ...
January 2017
120 pages
Global Cancer Immunotherapy Market Analysis & Forecast to 2022
Antibody Drug Conjugates (ADCs), Bispecific Monoclonal Antibodies, Cancer Vaccines, Cytokines, Interferons, Chimeric Antigen Receptor (CAR) T-Cell Therapy, PD-1/PD-L1 inhibitors, Dendritic Cells, Checkpoint Inhibitors, Adopted Cell Therapy (ACT) & IDO Inhibitors
US$ 4,900.00
... , Adectris, and Keytruda? What is the global market for cancer vaccines? What is the global market for cytokines in cancer immunotherapy? The projected market values for Nivolumab, Tecentriq, DCVax ...
January 2017
370 pages
Cervical Cancer Test Market & Patients (Pap Smear, HPV DNA, VIA) in Asia (Japan, Korea, Singapore, Malaysia, India, China, Thailand, Indonesia)
US$ 1,250.00
... the growth of cervical cancer test market in the developing countries. Cervical Cancer Test Market & Patients (Pap Smear, HPV DNA, VIA) in Asia (Japan, Korea, Singapore, Malaysia, India, China, Thailand, Indonesia) report published by Renub Research provides a comprehensive analysis of this market and future ...
January 2017
121 pages
2017 New Zealand Cancer Diagnostics Market: Emerging Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains—Test Volume and Sales Forecasts, Competitive Strategies, Opportunities for Suppliers
US$ 4,365.00
... years. Design criteria for new products. Alternative market penetration strategies. Potential market entry barriers and risks. Cancer Diagnostic Tests Analyzed in the ... spectroscopy. Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Assessments Strategic assessments of major ...
January 2017
535 pages
2017 United Arab Emirates Cancer Diagnostics Market: Emerging Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains—Test Volume and Sales Forecasts, Competitive Strategies, Opportunities for Suppliers
US$ 4,365.00
... others. Instrumentation Review Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling ... . Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies. Competitive Assessments Strategic assessments ...
January 2017
535 pages
Global Cancer Diagnostics Market Research Report 2017
US$ 2,850.00
Cancer Diagnostics Report by Material, Application, and Geography тАУ Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market ... Cancer Diagnostics Market; 3) the North American Cancer Diagnostics Market; 4) the European Cancer Diagnostics Market; 5) market ...
January 2017
156 pages
2017 Top 5 Checkpoint Inhibitors for Treating Cancer Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa
US$ 4,960.00
... , market share of top 5 players in these regions, from 2012 to 2017 (forecast), like North America (United States, Canada ... be divided into PD-1 inhibitors PD-L1 inhibitors CTLA-4 inhibitors Split by applications, this report focuses on sales, market share and growth rate of Checkpoint Inhibitors for Treating ...
December 2016
124 pages
